Novel strategy and latest research progress on treatment of acute graft versus host disease.
10.7534/j.issn.1009-2137.2014.02.052
- Author:
Bo TANG
1
,
2
;
Heng ZHU
3
;
Fan ZHOU
4
;
Yi ZHANG
5
Author Information
1. Base for Training Postgradnates, Shengyang Military Command Gerenal Hospital, Liaoning Medical College, Shengyang 110016, Liaoning Province, China
2. Department of Cell Biology, Institute of Basic Medical Sciences, Academy of Military Medical Sciences, Beijing 100850, China.
3. Department of Cell Biology, Institute of Basic Medical Sciences, Academy of Military Medical Sciences, Beijing 100850, China.
4. Base for Training Postgradnates, Shengyang Military Command Gerenal Hospital, Liaoning Medical College, Shengyang 110016, Liaoning Province, China. E-mail: zhoufan611@sina.com.cn.
5. Department of Cell Biology, Institute of Basic Medical Sciences, Academy of Military Medical Sciences, Beijing 100850, China. E-mail: zhangyi612@hotmail.com.
- Publication Type:Journal Article
- MeSH:
Acute Disease;
Graft vs Host Disease;
therapy;
Hematopoietic Stem Cell Transplantation;
adverse effects;
Humans;
Transplantation, Homologous;
adverse effects
- From:
Journal of Experimental Hematology
2014;22(2):543-548
- CountryChina
- Language:Chinese
-
Abstract:
Acute graft-versus-host disease (aGVHD) is the major complication associated with allogeneic hematopoietic stem cell transplantation (allo-HSCT) and the major cause of morbidity and mortality following allo-HSCT. Diagnosis of aGVHD is typically based on clinical symptoms and confirmed by biopsy. Once aGVHD has occurrence, the steroids should be the first choice of treatment. However, if the treatment with steroids failed, the prognosis would be poor. In recent years, the novel strategies for the treatment of aGVHD have been developed. In this article, the clinical features, pathogenesis and novel strategies, including mAb treatment, physical and cell therapies are briefly summarized.
